A Study of LY3985863 in Healthy Participants

Lilly

Status and phase: Active, not recruiting; Phase 1

Conditions: Healthy

Treatments: Drug: Placebo; Drug: LY3985863

Study type: Interventional

Funder types: Industry

Identifiers

NCT07030127

27292

J4Z-MC-GIDH (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to evaluate how well LY3985863 is tolerated and what side effects may occur in healthy Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin).

Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Enrollment: 24 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Are native Chinese participants
• Are overtly healthy
• Have body weight of at least 50.0 kilogram (kg) for male or 45.0 kg for female and a body mass index of 20.0 to 30.0 kilogram per square meter (kg/m²), inclusive
• Have a stable body weight within 3 months

Exclusion criteria

• Have known allergies to any components of the LY3985863 formulation
• Have concomitant disease known to influence skeletal muscle protein
• Have current or a history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs, of constituting a risk when taking the study medication or completing study procedures, or of interfering with the interpretation of the data
• Have a 12-lead echocardiogram (ECG) abnormality
• Have used within 3 months or intend to use medications during the study that promote weight loss

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

24 participants in 2 patient groups, including a placebo group

LY3985863

Experimental group

Description:

Administered subcutaneously (SC)

Treatment:

Drug: LY3985863

Placebo

Placebo Comparator group

Description:

Administered SC

Treatment:

Drug: Placebo